64321-24-0

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-6-chloronicotinamide is used as an intermediate in the synthesis of various pharmaceutical compounds due to its unique chemical structure and potential therapeutic properties. Its antineoplastic activity makes it a promising candidate for the development of anticancer drugs, targeting the inhibition of tumor growth and progression.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Amino-6-chloronicotinamide serves as a key component in the production of certain pesticides and herbicides. Its incorporation into these products leverages its potential to control or eliminate unwanted plant species or pests, thereby enhancing crop protection and yield.
Used in Antiviral Applications:
2-Amino-6-chloronicotinamide is utilized as an antiviral agent, capitalizing on its ability to inhibit viral replication and reduce the severity of viral infections. This application is particularly relevant in the development of treatments for various viral diseases, offering a potential therapeutic solution.
Used in Research and Development:
Due to its potential mutagenicity and unique chemical properties, 2-Amino-6-chloronicotinamide is employed in research and development settings. Scientists and researchers use 2-Amino-6-chloronicotinamide to explore its interactions with biological systems, investigate its effects on cellular processes, and develop new methodologies for its safe and effective use in various applications.

InChI:InChI=1/C6H6ClN3O/c7-4-2-1-3(6(9)11)5(8)10-4/h1-2H,(H2,8,10)(H2,9,11)

Upstream product

• 58584-92-2 2-amino-6-chloronicotinic acid 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 

Downstream Products

• 938443-19-7 7-chloropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
• 1378856-68-8 C₆H₇N₃O₂ 
• 552331-43-8 7-chloro-pyrido[2,3-d]pyrimidin-4-ol 
• 938440-64-3 KU-63794 
• 1009302-61-7 C₂₄H₂₉N₅O₄ 
• 1009302-80-0 C₂₅H₃₂N₆O₃ 
• 1009302-46-8 C₂₄H₃₁N₅O₄ 
• 1009302-47-9 C₂₃H₂₄N₆O₃ 
• 1009298-09-2 AZD₈₀₅₅ 
• 938443-20-0 2,4,7-trichloropyrido[2,3-d]pyrimidine 
• 938443-21-1 4-(2,7-dichloropyrido[2,3-d]pyrimidin-4-yl)morpholine 
• 938443-23-3 7-chloro-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine 
• 938443-29-9 7-(3-chloromethyl-4-methoxy-phenyl)-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine 
• 1424432-35-8 C₂₆H₃₄N₆O₃ 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS MTOR INHIBITORS

The present disclosure describes novel heterocyclic mTOR inhibitors and methods for preparing them. The pharmaceutical compositions comprising such mTOR inhibitors and methods of using them for treating cancer, infectious diseases, and other mTOR associated disorders are also described.

PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS

Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.

PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS

Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R7, G1 and G2, are defined herein.

SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

Disclosed are compounds of formula (I) that are useful as hepatitis C virus (HCV) NSSB polymerise inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NSSB polymerise activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. (I)

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014

The optimization of a potent and highly selective series of dual mTORC1 and mTORC2 inhibitors is described. An initial focus on improving cellular potency whilst maintaining or improving other key parameters, such as aqueous solubility and margins over hERG IC50, led to the discovery of the clinical candidate AZD8055 (14). Further optimization, particularly aimed at reducing the rate of metabolism in human hepatocyte incubations, resulted in the discovery of the clinical candidate AZD2014 (21).

HETEROCYCLIC JAK KINASE INHIBITORS

The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer

COMBINATION 059

This invention relates to a combination product, as defined herein, comprising a MEK inhibitor and a mTOR-selective inhibitor, and to methods for the production of an anti-cancer effect in a patient, which is accordingly useful in the treatment of cancer in a patient. More specifically the present invention relates to; a combination product, as defined herein, comprising a MEK inhibitor and a mTOR-selective inhibitor; a combination product, as defined herein, comprising a kit of parts comprising a MEK inhibitor and a mTOR-selective inhibitor; use of the combination product, as defined herein, in the treatment of cancer; a method of treating cancer comprising administering the combination product, as defined herein, to a patient. The combination product, as defined herein, and methods of the invention are also useful in the treatment of other diseases associated with the activity of MEK, and/or mTOR.

2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS

There is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula (1), and the use of a compound of Formula (1) as a medicament and in the treatment of cancer

PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS

There is provided compounds of formula (I), which are suitable for the treatment of cancer.